30岁以下非横纹肌肉瘤软组织肉瘤的风险分层治疗策略(ARST0332):儿童肿瘤学组前瞻性研究
该前瞻性研究在159家医院入组550例30岁以下NRSTS患者,基于肿瘤分级、大小、切除性和转移情况分为低、中、高危三组并给予风险适配治疗。
要点
- 治疗前临床特征可有效定义治疗失败风险并对年轻NRSTS患者进行风险分层。
- 多数低危患者可单纯手术治愈,避免辅助治疗的长期并发症。
- 中危和高危患者生存仍不理想,需要新疗法。
核心结论
- 治疗前临床特征可有效定义治疗失败风险,并据此对年轻NRSTS患者进行风险适配治疗分层。
- 多数低危患者可无需辅助治疗而治愈,从而避免已知的长期治疗并发症。
- 中危和高危患者生存仍欠佳,需要新疗法。
研究设计与样本
- 前瞻性研究,入组159家医院、3个国家的30岁以下新诊断NRSTS患者,要求Lansky或Karnofsky体能状态评分至少50。
- 550例合格患者入组,21例因分组错误被排除,529例可评估患者纳入分析。
- 按风险分为低危(n=222)、中危(n=227)、高危(n=80),按治疗分为单纯手术(n=205)、放疗(n=17)、放化疗(n=111)、新辅助放化疗(n=196)。
主要发现
- 治疗期间无毒性事件导致的死亡;9例出现意外4级不良事件(放化疗组2例,新辅助放化疗组7例),包括3例需手术的伤口并发症(均在新辅助放化疗组)。
关键数值与推荐
- 低危定义:非转移性R0或R1低级别肿瘤,或≤5 cm的R1高级别肿瘤。
- 中危定义:非转移性R0或R1 >5 cm高级别肿瘤,或任何大小或级别的未切除肿瘤。
- 高危定义:转移性肿瘤。
临床怎么用
- 治疗前临床特征可用于对年轻NRSTS患者进行风险分层并指导风险适配治疗。
- 低危患者多数可单纯手术治愈,避免辅助放疗和化疗的长期并发症。
- 中危和高危患者需考虑新疗法以改善生存。
局限性
- 21例患者因分组错误被排除,可能影响分析。
- 中危和高危患者生存仍不理想,当前治疗策略不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tumour grade, tumour size, resection potential, and extent of disease affect outcome in paediatric non-rhabdomyosarcoma soft-tissue sarcoma (NRSTS), but no risk stratification systems exist and the standard of care is poorly defined. We developed a risk stratification system from known prognostic factors and assessed it in the context of risk-adapted therapy for young patients with NRSTS. METHODS: In this prospective study, eligible patients enrolled in 159 hospitals in three countries were younger than 30 years, had a Lansky (patients ≤16 years) or Karnofsky (patients >16 years) performance status score of at least 50, and a new diagnosis of a WHO (2002 criteria) intermediate (rarely metastasising) or malignant soft-tissue tumour (apart from tumour types eligible for other Children's Oncology Group studies and tumours for which the therapy in this trial was deemed inappropriate), malignant peripheral nerve sheath tumour, non-metastatic and grossly resected dermatofibrosarcoma protuberans, undifferentiated embryonal sarcoma of the liver, or unclassified malignant soft-tissue sarcoma. Each patient was assigned to one of three risk groups and one of four treatment groups. Risk groups were: low (non-metastatic R0 or R1 low-grade, or ≤5 cm R1 high-grade tumour); intermediate (non-metastatic R0 or R1 >5 cm high-grade, or unresected tumour of any size or grade); or high (metastatic tumour). The treatment groups were surgery alone, radiotherapy (55·8 Gy), chemoradiotherapy (chemotherapy and 55·8 Gy radiotherapy), and neoadjuvant chemoradiotherapy (chemotherapy and 45 Gy radiotherapy, then surgery and radiotherapy boost based on margins with continued chemotherapy). Chemotherapy included six cycles of ifosfamide 3 g/m2 per dose intravenously on days 1-3 and five cycles of doxorubicin 37·5 mg/m2 per dose intravenously on days 1-2 every 3 weeks with sequence adjusted on the basis of timing of surgery or radiotherapy. The primary outcomes were event-free survival, overall survival, and the pattern of treatment failure. Analysis was done per protocol. This study has been completed and is registered with ClinicalTrials.gov, NCT00346164. FINDINGS: Between Feb 5, 2007, and Feb 10, 2012, 550 eligible patients were enrolled, of whom 21 were treated in the incorrect group and excluded from this analysis. 529 evaluable patients were included in the analysis: low-risk (n=222), intermediate-risk (n=227), high-risk (n=80); surgery alone (n=205), radiotherapy (n=17), chemoradiotherapy (n=111), and neoadjuvant chemoradiotherapy (n=196). At a median follow-up of 6·5 years (IQR 4·9-7·9), 5-year event-free survival and overall survival were: 88·9% (95% CI 84·0-93·8) and 96·2% (93·2-99·2) in the low-risk group; 65·0% (58·2-71·8) and 79·2% (73·4-85·0) in the intermediate-risk group; and 21·2% (11·4-31·1) and 35·5% (23·6-47·4) in the high-risk group, respectively. Risk group predicted event-free survival and overall survival (p<0·0001). No deaths from toxic events during treatment were reported. Nine patients had unexpected grade 4 adverse events (chemoradiotherapy group, n=2; neoadjuvant chemoradiotherapy group, n=7), including three wound complications that required surgery (all in the neoadjuvant chemoradiotherapy group). INTERPRETATION: Pre-treatment clinical features can be used to effectively define treatment failure risk and to stratify young patients with NRSTS for risk-adapted therapy. Most low-risk patients can be cured without adjuvant therapy, thereby avoiding known long-term treatment complications. Survival remains suboptimal for intermediate-risk and high-risk patients and novel therapies are needed. FUNDING: National Institutes of Health, St Baldrick's Foundation, Seattle Children's Foundation, American Lebanese Syrian Associated Charities.
引用
- Spunt SL, Million L, Chi YY, et al. A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study. Lancet Oncol. 2019. PMID: 31786124. doi:10.1016/S1470-2045(19)30672-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。